Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study

BACKGROUND: Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic dermatitis (AD) in clinical trials, but real-life experience is still limited. OBJECTIVES: The objective of this study was to evaluate the effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: De Greef, Axel, Ghislain, Pierre-Dominique, Bulinckx, Audrey, Coster, Alison, de Halleux, Céline, Damsin, Thomas, Jacobs, Marie-Claude, Suys, Erwin, Zoghaib, Samer, Baeck, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097792/
https://www.ncbi.nlm.nih.gov/pubmed/37012527
http://dx.doi.org/10.1007/s40261-023-01258-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097792/
https://www.ncbi.nlm.nih.gov/pubmed/37012527
http://dx.doi.org/10.1007/s40261-023-01258-7

Ejemplares similares